



## Complete Summary

---

### GUIDELINE TITLE

Determining the volume of residual urine by ultrasonography.

### BIBLIOGRAPHIC SOURCE(S)

Finnish Medical Society Duodecim. Determining the volume of residual urine by ultrasonography. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; 2004 Oct 3 [Various].

### GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Finnish Medical Society Duodecim. Determining the volume of residual urine by ultrasonography. In: EBM Guidelines. Evidence-Based Medicine [CD-ROM]. Helsinki, Finland: Duodecim Medical Publications Ltd.; 2000 May 9 [Various].

## COMPLETE SUMMARY CONTENT

SCOPE  
METHODOLOGY - including Rating Scheme and Cost Analysis  
RECOMMENDATIONS  
EVIDENCE SUPPORTING THE RECOMMENDATIONS  
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS  
QUALIFYING STATEMENTS  
IMPLEMENTATION OF THE GUIDELINE  
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES  
IDENTIFYING INFORMATION AND AVAILABILITY  
DISCLAIMER

## SCOPE

### DISEASE/CONDITION(S)

- Urinary incontinence
- Urinary symptoms
- Urinary tract infection
- A palpable mass in the lower abdomen
- Increased serum creatinine

### GUIDELINE CATEGORY

Diagnosis  
Evaluation

### **CLINICAL SPECIALTY**

Family Practice  
Internal Medicine

### **INTENDED USERS**

Health Care Providers  
Physicians

### **GUIDELINE OBJECTIVE(S)**

Evidence-Based Medicine Guidelines collect, summarize, and update the core clinical knowledge essential in general practice. The guidelines also describe the scientific evidence underlying the given treatment recommendations.

### **TARGET POPULATION**

- Individuals with urinary incontinence
- Elderly men with urinary symptoms
- Men with urinary tract infections
- Individuals with a palpable mass in the lower abdomen
- Individuals with increased serum creatinine

### **INTERVENTIONS AND PRACTICES CONSIDERED**

Determination of the volume of residual urine by ultrasonography of the urinary bladder

### **MAJOR OUTCOMES CONSIDERED**

Inter-observer reliability and validity of ultrasonic estimation of bladder volume

## **METHODOLOGY**

### **METHODS USED TO COLLECT/SELECT EVIDENCE**

Hand-searches of Published Literature (Primary Sources)  
Hand-searches of Published Literature (Secondary Sources)  
Searches of Electronic Databases

### **DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE**

The evidence reviewed was collected from the Cochrane database of systematic reviews and the database of abstracts of reviews of effectiveness (DARE). In addition, the Cochrane Library and medical journals were searched specifically for original publications.

**NUMBER OF SOURCE DOCUMENTS**

Not stated

**METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE**

Weighting According to a Rating Scheme (Scheme Given)

**RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE****Levels of Evidence**

- A. Strong research-based evidence. Multiple relevant, high-quality scientific studies with homogenic results.
- B. Moderate research-based evidence. At least one relevant, high-quality study or multiple adequate studies.
- C. Limited research-based evidence. At least one adequate scientific study.
- D. No research-based evidence. Expert panel evaluation of other information.

**METHODS USED TO ANALYZE THE EVIDENCE**

Systematic Review

**DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE**

Not applicable

**METHODS USED TO FORMULATE THE RECOMMENDATIONS**

Not stated

**RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS**

Not applicable

**COST ANALYSIS**

A formal cost analysis was not performed and published cost analyses were not reviewed.

**METHOD OF GUIDELINE VALIDATION**

Peer Review

**DESCRIPTION OF METHOD OF GUIDELINE VALIDATION**

Not stated

## RECOMMENDATIONS

### MAJOR RECOMMENDATIONS

The levels of evidence [A-D] supporting the recommendations are defined at the end of the "Major Recommendations" field.

#### Principles

- Any doctor can determine the volume of residual urine after brief education.

#### Indications

- Urinary incontinence (to rule out overflow)
- Urinary symptoms in elderly men
- Urinary tract infection in the male
- A palpable mass in the lower abdomen
- Increased serum creatinine (to rule out obstruction)

#### Techniques

- The patient voids.
- Keep the ultrasonography probe in a transverse position and find a view which shows the bladder at maximum size. Freeze the view and measure the horizontal (a) and vertical (b) dimensions of the bladder.
- Move the probe to a longitudinal position, find the maximum longitudinal dimension (c) of the bladder and measure it.
- The (minimum estimate of) residual urine volume =  $0.6 \times a \times b \times c$  (Nwosu et al., 1998; DARE-981930, 2000) [**B**]. If the dimensions are given in cm, the result is in mL.
- A volume exceeding 100 mL is abnormal, and a volume exceeding 200 mL is usually an indication of treatment.
- The volume of the prostate can be measured by using the same formula.

#### Examining the Full Bladder

- If you intend to determine the position and depth of the bladder before bladder puncture or percutaneous cystostomy, do not ask the patient to void, but perform ultrasonography with a full bladder.

#### Definitions:

#### Levels of Evidence

#### Levels of Evidence

- A. Strong research-based evidence. Multiple relevant, high-quality scientific studies with homogenic results.
- B. Moderate research-based evidence. At least one relevant, high-quality study or multiple adequate studies.

- C. Limited research-based evidence. At least one adequate scientific study.
- D. No research-based evidence. Expert panel evaluation of other information.

### **CLINICAL ALGORITHM(S)**

None provided

## **EVIDENCE SUPPORTING THE RECOMMENDATIONS**

### **REFERENCES SUPPORTING THE RECOMMENDATIONS**

[References open in a new window](#)

### **TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS**

Concise summaries of scientific evidence attached to the individual guidelines are the unique feature of the Evidence-Based Medicine Guidelines. The evidence summaries allow the clinician to judge how well-founded the treatment recommendations are. The type of supporting evidence is identified and graded for select recommendations (see the "Major Recommendations" field).

## **BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS**

### **POTENTIAL BENEFITS**

Appropriate determination of the volume of residual urine by ultrasonography

### **POTENTIAL HARMS**

Not stated

## **QUALIFYING STATEMENTS**

### **QUALIFYING STATEMENTS**

- Estimation of bladder volume by ultrasonography is both reliable and valid for clinical purposes, but the most appropriate formula for calculation cannot be determined on the basis of systematic review.
- The poor quality of the study designs and the potential elements of bias make it impossible to recommend the most valid formula for estimating bladder volume. The variation in bladder shape at different volumes would suggest that a single formula may be inappropriate at different bladder volumes.

## **IMPLEMENTATION OF THE GUIDELINE**

### **DESCRIPTION OF IMPLEMENTATION STRATEGY**

An implementation strategy was not provided.

## INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

### IOM CARE NEED

Getting Better

### IOM DOMAIN

Effectiveness

## IDENTIFYING INFORMATION AND AVAILABILITY

### BIBLIOGRAPHIC SOURCE(S)

Finnish Medical Society Duodecim. Determining the volume of residual urine by ultrasonography. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; 2004 Oct 3 [Various].

### ADAPTATION

Not applicable: The guideline was not adapted from another source.

### DATE RELEASED

2000 May 9 (revised 2004 Oct 3)

### GUIDELINE DEVELOPER(S)

Finnish Medical Society Duodecim - Professional Association

### SOURCE(S) OF FUNDING

Finnish Medical Society Duodecim

### GUIDELINE COMMITTEE

Editorial Team of EBM Guidelines

### COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

The group consisted of primary care physicians and specialists.

### FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

### GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: Finnish Medical Society Duodecim. Determining the volume of residual urine by ultrasonography. In: EBM Guidelines. Evidence-Based Medicine [CD-ROM]. Helsinki, Finland: Duodecim Medical Publications Ltd.; 2000 May 9 [Various].

#### **GUIDELINE AVAILABILITY**

This guideline is included in "EBM Guidelines. Evidence-Based Medicine" available from Duodecim Medical Publications, Ltd, PO Box 713, 00101 Helsinki, Finland; e-mail: [info@ebm-guidelines.com](mailto:info@ebm-guidelines.com); Web site: [www.ebm-guidelines.com](http://www.ebm-guidelines.com).

#### **AVAILABILITY OF COMPANION DOCUMENTS**

None available

#### **PATIENT RESOURCES**

None available

#### **NGC STATUS**

This summary was completed by ECRI on August 28, 2001. The information was verified by the guideline developer as of October 26, 2001. This summary was updated by ECRI on February 21, 2005.

#### **COPYRIGHT STATEMENT**

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

### **DISCLAIMER**

#### **NGC DISCLAIMER**

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2008 National Guideline Clearinghouse

Date Modified: 10/13/2008

